Zomedica Enterprise Value vs Working Capital Analysis

ZOM Stock

USD 0.15 0.01 7.14%

Zomedica Pharmaceuticals financial indicator trend analysis is more than just analyzing Zomedica Pharmaceuticals current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Zomedica Pharmaceuticals is a good investment. Please check the relationship between Zomedica Pharmaceuticals Enterprise Value and its Working Capital accounts. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zomedica Pharmaceuticals Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

Enterprise Value vs Working Capital

Enterprise Value vs Working Capital Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Zomedica Pharmaceuticals Enterprise Value account and Working Capital. At this time, the significance of the direction appears to have almost no relationship.

The correlation between Zomedica Pharmaceuticals' Enterprise Value and Working Capital is 0.17. Overlapping area represents the amount of variation of Enterprise Value that can explain the historical movement of Working Capital in the same time period over historical financial statements of Zomedica Pharmaceuticals Corp, assuming nothing else is changed. The correlation between historical values of Zomedica Pharmaceuticals' Enterprise Value and Working Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Enterprise Value of Zomedica Pharmaceuticals Corp are associated (or correlated) with its Working Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Working Capital has no effect on the direction of Enterprise Value i.e., Zomedica Pharmaceuticals' Enterprise Value and Working Capital go up and down completely randomly.

Correlation Coefficient

0.17

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Enterprise Value

Enterprise Value (or EV) is usually referred to as Zomedica Pharmaceuticals theoretical takeover price. In the event of an acquisition, an acquirer would have to take on Zomedica Pharmaceuticals debt, but would also pocket its cash. Enterprise Value is more accurate representation of Zomedica Pharmaceuticals value than its market capitalization because it takes into account all of Zomedica Pharmaceuticals Corp existing debt. A measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization that includes the market capitalization, plus total debt, minority interest and preferred shares, minus total cash and cash equivalents.

Working Capital

The difference between a company's current assets and current liabilities, indicating the liquidity and operational efficiency of the business.

Most indicators from Zomedica Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Zomedica Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zomedica Pharmaceuticals Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

At this time, Zomedica Pharmaceuticals' Selling General Administrative is very stable compared to the past year. As of the 5th of January 2025, Enterprise Value is likely to grow to about 175.7 M, though Tax Provision is likely to grow to (2.4 M).

	2022	2023	2024	2025 (projected)
Depreciation And Amortization	4.0M	6.3M	7.2M	7.6M
Interest Income	2.5M	5.6M	6.5M	6.8M

Depreciation And Amortization Interest Income

Zomedica Pharmaceuticals fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Other Stockholder Equity	Total Liab	Total Current Assets	Net Receivables	Common Stock Shares Outstanding	Other Current Assets	Common Stock	Net Tangible Assets	Property Plant And Equipment Net	Accounts Payable	Non Current Liabilities Total	Property Plant And Equipment Gross	Short Long Term Debt	Short Term Debt	Intangible Assets
Total Assets		-0.36	0.93	1.0	-0.45	-0.96	0.51	0.96	0.47	0.21	0.93	0.82	0.88	0.94	0.93	0.99	0.78	-0.14	1.0	0.81	0.91	0.52	0.82	0.83	0.95	0.96
Other Current Liab	-0.36		-0.23	-0.37	0.04	0.23	-0.05	-0.38	0.38	0.77	-0.28	-0.17	-0.1	-0.29	-0.34	-0.29	-0.14	0.18	-0.33	-0.21	-0.23	0.08	-0.23	-0.26	-0.31	-0.35
Total Current Liabilities	0.93	-0.23		0.93	-0.16	-0.96	0.22	0.98	0.46	0.3	0.75	0.92	0.88	0.78	0.98	0.96	0.79	-0.12	0.91	0.94	1.0	0.44	0.94	0.83	0.9	0.98
Total Stockholder Equity	1.0	-0.37	0.93		-0.45	-0.95	0.51	0.96	0.46	0.19	0.93	0.82	0.86	0.94	0.92	0.99	0.78	-0.14	1.0	0.81	0.91	0.51	0.82	0.83	0.94	0.96
Net Debt	-0.45	0.04	-0.16	-0.45		0.36	-1.0	-0.17	-0.18	-0.13	-0.75	0.0	-0.36	-0.72	-0.09	-0.42	-0.28	0.07	-0.5	0.05	-0.11	-0.51	0.04	-0.42	-0.41	-0.22
Retained Earnings	-0.96	0.23	-0.96	-0.95	0.36		-0.42	-0.93	-0.41	-0.31	-0.86	-0.83	-0.92	-0.88	-0.92	-0.97	-0.83	0.13	-0.94	-0.85	-0.94	-0.59	-0.85	-0.91	-0.94	-0.93
Cash	0.51	-0.05	0.22	0.51	-1.0	-0.42		0.24	0.22	0.15	0.79	0.07	0.42	0.77	0.16	0.48	0.31	-0.08	0.56	0.03	0.17	0.53	0.03	0.47	0.46	0.29
Non Current Assets Total	0.96	-0.38	0.98	0.96	-0.17	-0.93	0.24		0.45	0.17	0.78	0.9	0.84	0.8	0.99	0.96	0.76	-0.13	0.94	0.92	0.98	0.39	0.93	0.78	0.91	0.99
Non Currrent Assets Other	0.47	0.38	0.46	0.46	-0.18	-0.41	0.22	0.45		0.67	0.42	0.51	0.52	0.43	0.46	0.48	0.31	0.07	0.5	0.45	0.44	0.41	0.44	0.13	0.49	0.47
Other Assets	0.21	0.77	0.3	0.19	-0.13	-0.31	0.15	0.17	0.67		0.22	0.31	0.43	0.22	0.19	0.27	0.44	0.13	0.21	0.18	0.3	0.43	0.16	0.21	0.3	0.16
Cash And Short Term Investments	0.93	-0.28	0.75	0.93	-0.75	-0.86	0.79	0.78	0.42	0.22		0.6	0.81	1.0	0.72	0.91	0.7	-0.14	0.94	0.58	0.72	0.63	0.58	0.8	0.88	0.79
Other Stockholder Equity	0.82	-0.17	0.92	0.82	0.0	-0.83	0.07	0.9	0.51	0.31	0.6		0.74	0.63	0.92	0.85	0.68	0.21	0.8	0.9	0.92	0.29	0.91	0.65	0.76	0.9
Total Liab	0.88	-0.1	0.88	0.86	-0.36	-0.92	0.42	0.84	0.52	0.43	0.81	0.74		0.83	0.84	0.91	0.7	-0.16	0.88	0.79	0.85	0.81	0.77	0.9	0.96	0.83
Total Current Assets	0.94	-0.29	0.78	0.94	-0.72	-0.88	0.77	0.8	0.43	0.22	1.0	0.63	0.83		0.75	0.93	0.72	-0.14	0.96	0.61	0.75	0.62	0.61	0.81	0.9	0.82
Net Receivables	0.93	-0.34	0.98	0.92	-0.09	-0.92	0.16	0.99	0.46	0.19	0.72	0.92	0.84	0.75		0.94	0.72	-0.13	0.91	0.96	0.98	0.39	0.96	0.77	0.88	0.99
Common Stock Shares Outstanding	0.99	-0.29	0.96	0.99	-0.42	-0.97	0.48	0.96	0.48	0.27	0.91	0.85	0.91	0.93	0.94		0.79	-0.12	0.99	0.85	0.94	0.56	0.85	0.87	0.96	0.96
Other Current Assets	0.78	-0.14	0.79	0.78	-0.28	-0.83	0.31	0.76	0.31	0.44	0.7	0.68	0.7	0.72	0.72	0.79		-0.03	0.74	0.55	0.79	0.4	0.56	0.71	0.79	0.7
Common Stock	-0.14	0.18	-0.12	-0.14	0.07	0.13	-0.08	-0.13	0.07	0.13	-0.14	0.21	-0.16	-0.14	-0.13	-0.12	-0.03		-0.14	-0.12	-0.12	-0.14	-0.12	-0.2	-0.16	-0.14
Net Tangible Assets	1.0	-0.33	0.91	1.0	-0.5	-0.94	0.56	0.94	0.5	0.21	0.94	0.8	0.88	0.96	0.91	0.99	0.74	-0.14		0.8	0.89	0.55	0.81	0.82	0.94	0.95
Property Plant And Equipment Net	0.81	-0.21	0.94	0.81	0.05	-0.85	0.03	0.92	0.45	0.18	0.58	0.9	0.79	0.61	0.96	0.85	0.55	-0.12	0.8		0.94	0.33	1.0	0.71	0.76	0.94
Accounts Payable	0.91	-0.23	1.0	0.91	-0.11	-0.94	0.17	0.98	0.44	0.3	0.72	0.92	0.85	0.75	0.98	0.94	0.79	-0.12	0.89	0.94		0.39	0.95	0.81	0.87	0.97
Non Current Liabilities Total	0.52	0.08	0.44	0.51	-0.51	-0.59	0.53	0.39	0.41	0.43	0.63	0.29	0.81	0.62	0.39	0.56	0.4	-0.14	0.55	0.33	0.39		0.3	0.7	0.72	0.39
Property Plant And Equipment Gross	0.82	-0.23	0.94	0.82	0.04	-0.85	0.03	0.93	0.44	0.16	0.58	0.91	0.77	0.61	0.96	0.85	0.56	-0.12	0.81	1.0	0.95	0.3		0.7	0.76	0.95
Short Long Term Debt	0.83	-0.26	0.83	0.83	-0.42	-0.91	0.47	0.78	0.13	0.21	0.8	0.65	0.9	0.81	0.77	0.87	0.71	-0.2	0.82	0.71	0.81	0.7	0.7		0.87	0.78
Short Term Debt	0.95	-0.31	0.9	0.94	-0.41	-0.94	0.46	0.91	0.49	0.3	0.88	0.76	0.96	0.9	0.88	0.96	0.79	-0.16	0.94	0.76	0.87	0.72	0.76	0.87		0.88
Intangible Assets	0.96	-0.35	0.98	0.96	-0.22	-0.93	0.29	0.99	0.47	0.16	0.79	0.9	0.83	0.82	0.99	0.96	0.7	-0.14	0.95	0.94	0.97	0.39	0.95	0.78	0.88

Click cells to compare fundamentals

Zomedica Pharmaceuticals Account Relationship Matchups

Zomedica Pharmaceuticals fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	66.1M	280.4M	279.6M	253.2M	291.2M	305.7M
Other Current Liab	1.2M	45.1K	(1.0M)	107K	96.3K	91.5K
Total Current Liabilities	2.0M	4.3M	7.8M	9.0M	10.4M	10.9M
Total Stockholder Equity	51.1M	270.9M	267.4M	240.0M	276.0M	289.8M
Net Debt	(60.1M)	(193.6M)	(25.7M)	(10.2M)	(9.2M)	(9.7M)
Retained Earnings	(69.0M)	(119.4M)	(136.4M)	(170.9M)	(153.8M)	(146.1M)
Cash	62.0M	195.0M	27.4M	13.0M	14.9M	28.1M
Non Current Assets Total	3.3M	80.0M	156.1M	153.3M	176.3M	185.1M
Non Currrent Assets Other	1M	659.1K	453K	1.1M	1.2M	1.3M
Cash And Short Term Investments	62.0M	195.0M	115.1M	90.5M	104.1M	109.3M
Liabilities And Stockholders Equity	66.1M	280.4M	279.6M	253.2M	291.2M	305.7M
Other Stockholder Equity	2.8M	9.3M	23.7M	29.9M	34.4M	36.1M
Total Liab	15.1M	9.5M	12.2M	13.2M	15.2M	15.9M
Total Current Assets	62.9M	200.4M	123.5M	99.9M	114.9M	120.6M
Net Receivables	146.2K	765.5K	1.9M	2.2M	2.5M	2.7M
Common Stock Shares Outstanding	364.4M	956.5M	979.9M	979.9M	1.1B	1.2B
Other Current Assets	727.8K	1.8M	3.8M	2.1M	2.4M	1.4M
Accumulated Other Comprehensive Income	459.6K	1.7K	(843K)	48K	43.2K	59.2K
Common Stock	38.6M	104.8M	381.0M	381.0M	342.9M	325.7M
Net Tangible Assets	(10.4M)	50.7M	194.1M	161.6M	185.9M	195.1M
Property Plant And Equipment Net	1.9M	2.5M	9.2M	25.3M	29.1M	30.5M
Accounts Payable	1.2M	3.2M	6.7M	7.7M	8.8M	9.3M
Common Stock Total Equity	38.6M	459.6	381.0M	381.0M	438.1M	460.0M
Retained Earnings Total Equity	(52.1M)	(69.0M)	(119.4M)	(136.4M)	(122.8M)	(116.6M)
Non Current Liabilities Total	13.0M	5.2M	4.4M	4.1M	4.8M	3.3M
Property Plant And Equipment Gross	583.01	3.4M	10.4M	27.3M	31.4M	33.0M
Short Term Debt	780.1K	829.7K	1.3M	916K	1.1M	1.1M
Intangible Assets	376.6K	33.5M	41.8M	55.4M	63.7M	66.9M
Property Plant Equipment	1.8M	583.0K	2.5M	6.8M	7.8M	8.2M
Cash And Equivalents	510.6K	62.0M	195.0M	27.4M	31.5M	46.1M
Capital Surpluse	3.6M	14.8M	9.3M	23.7M	27.2M	28.6M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Zomedica Pharmaceuticals is a strong investment it is important to analyze Zomedica Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zomedica Pharmaceuticals' future performance. For an informed investment choice regarding Zomedica Stock, refer to the following important reports:

How To Invest In Zomedica

Details

Is Zomedica Stock a good investment?

Details

What is Zomedica Pharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zomedica Pharmaceuticals Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zomedica Pharmaceuticals. If investors know Zomedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zomedica Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.06)

Revenue Per Share

0.027

Quarterly Revenue Growth

0.018

Return On Assets

(0.09)

Return On Equity

(0.24)

The market value of Zomedica Pharmaceuticals is measured differently than its book value, which is the value of Zomedica that is recorded on the company's balance sheet. Investors also form their own opinion of Zomedica Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zomedica Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zomedica Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zomedica Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Zomedica Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zomedica Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zomedica Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Zomedica Enterprise Value vs Working Capital Analysis

Enterprise Value vs Working Capital

Enterprise Value vs Working Capital Correlation Analysis

Correlation Coefficient

Enterprise Value

Working Capital

Zomedica Pharmaceuticals fundamental ratios Correlations

Zomedica Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Zomedica Pharmaceuticals fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Net Tangible Assets	+ 1.0	Total Assets
Accounts Payable	+ 1.0	Total Current Liabilities
Net Tangible Assets	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Cash And Short Term Investments
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net

Cash	- 1.0	Net Debt
Common Stock Shares Outstanding	- 0.97	Retained Earnings
Retained Earnings	- 0.96	Total Current Liabilities
Retained Earnings	- 0.96	Total Assets
Retained Earnings	- 0.95	Total Stockholder Equity
Short Term Debt	- 0.94	Retained Earnings